论文部分内容阅读
目的 :探索耐药相关基因MDR1和拓扑异构酶TOPOⅡ在乳腺癌中的表达、与肿瘤标志物的关系及其与临床病理特征的关系 ,同时也探讨MDR1和TOPOⅡ与C -erbB - 2共表达的临床意义。方法 :运用免疫组化方法对 94例乳腺癌组织切片MDR1、TOPOⅡ、C -erbB - 2、EGFR、P5 3、PCNA、nm2 3、ER、PR的表达进行检测。结果 :MDR1、TOPOⅡ和C -erbB - 2在乳腺癌中的阳性率分别为 5 2 .1%、4 8.9%和 4 6 .8% ;MDR1和TOPOⅡ均与C -erbB - 2、EGFR、P5 3有相关关系 ,MDR1还和PCNA有关 ;MDR1和TOPOⅡ单独与各项临床病理特征均无关系 ,但TOPOⅡ与C -erbB - 2或MDR1与C -erbB - 2共表达都与肿瘤大小和临床分期有相关关系 ,尤其是TOPOⅡ与C -erbB - 2共表达相关非常显著。结论 :MDR1和TOPOⅡ不仅是肿瘤多药耐药的重要指标 ,它们与C -erbB - 2共表达在对评价乳腺癌肿瘤大小及临床分期上有重要意义。
OBJECTIVE: To investigate the expression of MDR1 and TOPOⅡ in breast cancer and its relationship with tumor markers and their clinicopathological features, and to explore the co-expression of MDR1 and TOPOⅡ with C-erbB-2 The clinical significance. Methods: The expressions of MDR1, TOPOⅡ, C-erbB - 2, EGFR, P53, PCNA, nm23, ER and PR in 94 cases of breast cancer tissues were detected by immunohistochemistry. Results: The positive rates of MDR1, TOPO Ⅱ and C - erbB - 2 in breast cancer were 52.1%, 49.9% and 46.6%, respectively. The positive rates of MDR1 and TOPO Ⅱ were all significantly higher than those of C - erbB - 2, EGFR, 3, MDR1 and PCNA were also related. MDR1 and TOPOⅡ had no relationship with clinicopathological features alone. However, co-expression of TOPOⅡ and C-erbB-2 or MDR1 and C-erbB-2 were correlated with tumor size and clinical stage There is a correlation, especially TOPO Ⅱ and C-erbB - 2 coexpression is very significant. Conclusion: MDR1 and TOPO Ⅱ are not only important markers of multidrug resistance in tumors, but they are important for evaluating the size and clinical stage of breast cancer with co-expression of C-erbB-2.